Cosmo announces successful outcome of Rifamycin 600mg Phase II trial in IBS-D
Cosmo Pharmaceuticals N.V. today announced the successful outcome of its Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D).